Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Feb 23;20(1):37.
doi: 10.1186/s12943-021-01331-9.

Intratumoral heterogeneity as a predictive biomarker in anti-PD-(L)1 therapies for non-small cell lung cancer

Wenfeng Fang #  1 , Haoxuan Jin #  2   3 , Huaqiang Zhou #  1 , Shaodong Hong #  1 , Yuxiang Ma  1 , Yaxiong Zhang  1 , Xiaofan Su  2   3 , Longyun Chen  2   3 , Yunpeng Yang  1 , Shengqiang Xu  2   3 , Yuwei Liao  4 , Yuming He  3 , Hongyun Zhao  1 , Yan Huang  1 , Zhibo Gao  5   6 , Li Zhang  7
Affiliations

Intratumoral heterogeneity as a predictive biomarker in anti-PD-(L)1 therapies for non-small cell lung cancer

Wenfeng Fang et al. Mol Cancer. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no potential conflicts of interest.

Figures

Fig. 1
Fig. 1
Intratumoral heterogeneity alone or combined with TMB is associated with clinical outcome in SYSUCC NSCLC cohort. a Distribution of intratumoral heterogeneity (ITH) in SYSUCC NSCLC cohort. Top histogram, counts of clonal mutation (indigo) and subclonal mutation (green) of each patient; lower histogram, proportion clonal mutation and subclonal mutation of each patient. b Boxplots of the distribution of ITH value between patients with DCB and NDB, and the distribution of ITH between patients with objective response (ORR) and non-object response (NOR). c Barplots of DCB rate and ORR between ITH-L group and ITH-H group. d ITH-L is associated with better progression-free survival. e The correlation between ITH and TMB. f ITH-L is associated with better progress-free survival in TMB-L subgroup. g Barplot of durable clinical benefit rate among three groups of TMB-H, TMB-L&ITH-L and TMB-L&ITH-H. h Progression-free survival plot among three groups of TMB-H, TMB-L&ITH-L and TMB-L&ITH-H
Fig. 2
Fig. 2
Mechanism of intratumoral heterogeneity affecting clinical outcome of immunotherapy in tumor neoantigen and microenvironment. a Neoantigen score of top 100 putative neoantigen of each patient between ITH-L group and ITH-H group. b Association between clonal neoantigen and ITH. The proportion of clonal neoantigen in patients of different ITH level is shown at left violin plot and neoantigen score difference between clonal and subclonal neoantigen is shown at right violin plot. c Neoantigen scores of clonal neoantigens differ across ITH groups (left) while neoantigen scores of subclonal neoantigens don’t (right). d Distribution of Neoantigen Fitness of each patient in ITH-H group and ITH-L group. e Immune subtypes proportion of ITH-H and ITH-L group in Liu cohort (left), TCGA-LUAD (middle), TCGA-LUSC (right). f Schematic representation of potential interplay of tumor mutation burden and intratumoral heterogeneity. High TMB is a positive factor to the response of immunotherapy while high ITH is a negative factor to the response of immunotherapy. In the situation when patient had high TMB with low ITH, the major clone in the tumor contained a relatively higher number and higher proportion of immunogenic neoantigens that responded to T cells (Top left). When patient had high TMB but with high ITH, the proportion of clonal immunogenic neoantigens decreased and patient responded less to T cells during ICIs therapy (Bottom left). When patient had low TMB with low ITH, the total number of immunogenic neoantigens decreased though the proportion of clonal immunogenic neoantigens still remained relative higher. Therefore, the clinical outcomes of TMB-L&ITH-L patients might be worse than that of TMB-H&ITH-L (Top right). However, when patient with low TMB and high ITH received the worst clinical outcome due to the small number and low proportion of clonal immunogenic neoantigens (Bottom right)
See this image and copyright information in PMC

References

    1. Vogelstein B, Papadopoulos N, Velculescu VE, et al. Cancer genome landscapes. Science. 2013;339(6127):1546–1558. doi: 10.1126/science.1235122. - DOI - PMC - PubMed
    1. Landau DA, Carter SL, Stojanov P, et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell. 2013;152(4):714–726. doi: 10.1016/j.cell.2013.01.019. - DOI - PMC - PubMed
    1. Mroz EA, Rocco JW. MATH, a novel measure of intratumor genetic heterogeneity, is high in poor-outcome classes of head and neck squamous cell carcinoma. Oral Oncol. 2013;49(3):211–215. doi: 10.1016/j.oraloncology.2012.09.007. - DOI - PMC - PubMed
    1. Patel AP, Tirosh I, Trombetta JJ, et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science. 2014;344(6190):1396–1401. doi: 10.1126/science.1254257. - DOI - PMC - PubMed
    1. Zhang J, Fujimoto J, Zhang J, et al. Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science. 2014;346(6206):256–259. doi: 10.1126/science.1256930. - DOI - PMC - PubMed

Publication types

Substances